Role of specific DNA mutations in the peripheral blood of colorectal cancer patients for the assessment of tumor stage and residual disease following tumor resection

Norcic,Gregor; Jelenc,Franc; Cerkovnik,Petra; Stegel,Vida; Novakovic,Srdjan

doi:10.3892/ol.2016.5078

Role of specific DNA mutations in the peripheral blood of colorectal cancer patients for the assessment of tumor stage and residual disease following tumor resection

Authors:
- Gregor Norcic
- Franc Jelenc
- Petra Cerkovnik
- Vida Stegel
- Srdjan Novakovic
View Affiliations

Affiliations: Clinical Department of Abdominal Surgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia, Department of Molecular Diagnostics, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia
Published online on: September 1, 2016 https://doi.org/10.3892/ol.2016.5078
Pages: 3356-3362
Copyright: © Norcic et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, the detection of tumor-specific KRAS proto‑oncogene, GTPase (KRAS) and B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutations in the peripheral blood of colorectal cancer (CRC) patients at all stages and adenomas was used for the estimation of disease stage prior to surgery and for residual disease following surgery. A total of 65 CRC patients were enrolled. The primary tumor tested positive for the specific mutations (KRAS mutations in codons 12, 13, 61, 117 or 146 and BRAF mutations in codon 600) in 35 patients. In all these patients, the specimen of normal bowel resected with the tumor was also tested for the presence of the same mutations in order to exclude the germ‑line mutations. Only patients who tested positive for the specific mutation in the primary tumor were included in further analysis for the presence of tumor‑specific mutation in the peripheral blood. No statistically significant differences were found between the detection rates of tumor mutations in the blood and different tumor stages (P=0.491). However, statistically significant differences in the proportions of patients with detected tumor‑specific DNA mutations in the peripheral blood were found when comparing the groups of patients with R0 and R2 resections (P=0.038). Tumor‑specific DNA mutations in the peripheral blood were more frequently detected in the patients with an incomplete surgical clearance of the tumor due to macroscopic residual disease (R2 resections). Therefore, the study concludes that the follow‑up of somatic KRAS‑ and BRAF‑mutated DNA in the peripheral blood of CRC patients may be useful in assessing the surgical clearance of the disease.

View Figures

View References

1	Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
2	Pita-Fernández S, Alhayek-Aí M, González-Martín C, López-Calviño B, Seoane-Pillado T and Pértega-Díaz S: Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: A systematic review and meta-analysis. Ann Oncol. 26:644–656. 2015. View Article : Google Scholar : PubMed/NCBI
3	Compton CC: Colorectal carcinoma: Diagnostic, prognostic, and molecular features. Mod Pathol. 16:376–388. 2003. View Article : Google Scholar : PubMed/NCBI
4	Wittekind C, Compton CC, Greene FL and Sobin LH: TNM residual tumor classification revisited. Cancer. 94:2511–2516. 2002. View Article : Google Scholar : PubMed/NCBI
5	Wittekind C: Problems with residual tumor classification, particularly R1. Chirurg. 78:785–791. 2007.(In German). View Article : Google Scholar : PubMed/NCBI
6	Greene FL: Cancer staging in outcomes assessment. J Surg Oncol. 110:616–620. 2014. View Article : Google Scholar : PubMed/NCBI
7	Nicholls J: Commentary. Colorectal Dis. 14:1074–1075. 2012. View Article : Google Scholar : PubMed/NCBI
8	Tsouma A, Aggeli C, Pissimissis N, Lembessis P, Zografos GN and Koutsilieris M: Circulating tumor cells in colorectal cancer: Detection methods and clinical significance. Anticancer Res. 28:3945–3960. 2008.PubMed/NCBI
9	Sergeant G, Penninckx F and Topal B: Quantitative RT-PCR detection of colorectal tumor cells in peripheral blood-a systematic review. J Surg Res. 150:144–152. 2008. View Article : Google Scholar : PubMed/NCBI
10	Peach G, Kim C, Zacharakis E, Purkayastha S and Ziprin P: Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: A systematic review. Br J Cancer. 102:1327–1334. 2010. View Article : Google Scholar : PubMed/NCBI
11	Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, Diener MK, Büchler MW, Koch M and Weitz J: Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 138:1714–1726. 2010. View Article : Google Scholar : PubMed/NCBI
12	Shen CX, Hu LH, Xia L and Li YR: Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients. Jpn J Clin Oncol. 38:770–776. 2008. View Article : Google Scholar : PubMed/NCBI
13	Weinberg RA: Leaving home early: Reexamination of the canonical models of tumor progression. Cancer Cell. 14:283–284. 2008. View Article : Google Scholar : PubMed/NCBI
14	Klein CA: Cancer. The metastasis cascade. Science. 321:1785–1787. 2008. View Article : Google Scholar : PubMed/NCBI
15	Allan AL and Keeney M: Circulating tumor cell analysis: Technical and statistical considerations for application to the clinic. J Oncol. 2010:4262182010. View Article : Google Scholar : PubMed/NCBI
16	Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, et al: Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 20:1223–1229. 2009. View Article : Google Scholar : PubMed/NCBI
17	Dotan E, Cohen SJ, Alpaugh KR and Meropol NJ: Circulating tumor cells: Evolving evidence and future challenges. Oncologist. 14:1070–1082. 2009. View Article : Google Scholar : PubMed/NCBI
18	Maheswaran S and Haber DA: Circulating tumor cells: A window into cancer biology and metastasis. Curr Opin Genet Dev. 20:96–99. 2010. View Article : Google Scholar : PubMed/NCBI
19	Knijn N, Mekenkamp LJ, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma S, van Krieken JH, et al: KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 104:1020–1026. 2011. View Article : Google Scholar : PubMed/NCBI
20	Mostert B, Jiang Y, Sieuwerts AM, Wang H, Bolt-de Vries J, Biermann K, Kraan J, Lalmahomed Z, van Galen A, de Weerd V, et al: KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer. 133:130–141. 2013. View Article : Google Scholar : PubMed/NCBI
21	Pantel K and Alix-Panabières C: Real-time liquid biopsy in cancer patients: Fact or fiction? Cancer Res. 73:6384–6388. 2013. View Article : Google Scholar : PubMed/NCBI
22	Bidard FC, Weigelt B and Reis-Filho JS: Going with the flow: From circulating tumor cells to DNA. Sci Transl Med. 5:207ps142013. View Article : Google Scholar : PubMed/NCBI
23	Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al: Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
24	Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al: Circulating mutant DNA to assess tumor dynamics. Nat Med. 14:985–990. 2008. View Article : Google Scholar : PubMed/NCBI
25	Iinuma H, Okinaga K, Egami H, Mimori K, Hayashi N, Nishida K, Adachi M, Mori M and Sasako M: Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. Int J Oncol. 28:297–306. 2006.PubMed/NCBI
26	Tsouma A, Aggeli C, Lembessis P, Zografos GN, Korkolis DP, Pectasides D, Skondra M, Pissimissis N, Tzonou A and Koutsilieris M: Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. World J Gastroenterol. 16:5965–5974. 2010.PubMed/NCBI
27	Lin JK, Lin PC, Lin CH, Jiang JK, Yang SH, Liang WY, Chen WS and Chang SC: Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: Based on the mutation spectra detected in primary tumors. Ann Surg Oncol. 21(Suppl 4): S680–S686. 2014. View Article : Google Scholar : PubMed/NCBI
28	Wang JY, Wu CH, Lu CY, Hsieh JS, Wu DC, Huang SY and Lin SR: Molecular detection of circulating tumor cells in the peripheral blood of patients with colorectal cancer using RT-PCR: Significance of the prediction of postoperative metastasis. World J Surg. 30:1007–1013. 2006. View Article : Google Scholar : PubMed/NCBI
29	Uen YH, Lu CY, Tsai HL, Yu FJ, Huang MY, Cheng TL, Lin SR and Wang JY: Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I–III colorectal cancer after curative resection. Ann Surg Oncol. 15:2120–2128. 2008. View Article : Google Scholar : PubMed/NCBI
30	Ryan BM, Lefort F, McManus R, Daly J, Keeling PW, Weir DG and Kelleher D: A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: Strong prognostic indicator in postoperative follow up. Gut. 52:101–108. 2003. View Article : Google Scholar : PubMed/NCBI
31	Hsieh JS, Lin SR, Chang MY, Chen FM, Lu CY, Huang TJ, Huang YS, Huang CJ and Wang JY: APC, K-ras, and p53 gene mutations in colorectal cancer patients: Correlation to clinicopathologic features and postoperative surveillance. Am Surg. 71:336–343. 2005.PubMed/NCBI
32	Frattini M, Gallino G, Signoroni S, Balestra D, Lusa L, Battaglia L, Sozzi G, Bertario L, Leo E, Pilotti S and Pierotti MA: Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett. 263:170–181. 2008. View Article : Google Scholar : PubMed/NCBI
33	Lecomte T, Ceze N, Dorval E and Laurent-Puig P: Circulating free tumor DNA and colorectal cancer. Gastroenterol Clin Biol. 34:662–681. 2010. View Article : Google Scholar : PubMed/NCBI
34	Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ and Gocke CD: Somatic mutation screening: Identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst. 92:918–923. 2000. View Article : Google Scholar : PubMed/NCBI
35	Lu CY, Uen YH, Tsai HL, Chuang SC, Hou MF, Wu DC, Juo SH, Lin SR and Wang JY: Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: Prognostic significance of detection for early relapse. Br J Cancer. 104:1178–1184. 2011. View Article : Google Scholar : PubMed/NCBI
36	Allen-Mersh TG, McCullough TK, Patel H, Wharton RQ, Glover C and Jonas SK: Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma. Br J Surg. 94:96–105. 2007. View Article : Google Scholar : PubMed/NCBI
37	Lindforss U, Zetterquist H, Papadogiannakis N and Olivecrona H: Persistence of K-ras mutations in plasma after colorectal tumor resection. Anticancer Res. 25:657–661. 2005.PubMed/NCBI
38	Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al: The genomic landscapes of human breast and colorectal cancers. Science. 318:1108–1113. 2007. View Article : Google Scholar : PubMed/NCBI
39	Ličar A, Cerkovnik P and Novaković S: Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Med Oncol. 28:1048–1053. 2011. View Article : Google Scholar : PubMed/NCBI
40	Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 366:883–892. 2012. View Article : Google Scholar : PubMed/NCBI
41	Bork U, Grützmann R, Rahbari NN, Schölch S, Distler M, Reissfelder C, Koch M and Weitz J: Prognostic relevance of minimal residual disease in colorectal cancer. World J Gastroenterol. 20:10296–10304. 2014. View Article : Google Scholar : PubMed/NCBI
42	Yong E: Cancer biomarkers: Written in blood. Nature. 511:524–526. 2014. View Article : Google Scholar : PubMed/NCBI
43	Chapuis PH, Bokey L, Chan C and Dent OF: Colorectal cancer staging revisited: Time for critical evaluation? Colorectal Dis. 14:1043–1044. 2012. View Article : Google Scholar : PubMed/NCBI
44	Wittekind C and Oberschmid B: TNM classification of malignant tumors 2010: General aspects and amendments in the general section. Pathologe. 31:333–334, 336–338. 2010.(In German). View Article : Google Scholar : PubMed/NCBI